

303, Washington, DC 20580, (202) 326-3100.

By Directions of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 02-1477 Filed 1-18-02; 8:45 am]

BILLING CODE 6750-01-M

FEDERAL TRADE COMMISSION

Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules

Section 7A of the Clayton Act, 15 U.S.C 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Federal Trade Commission and the Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section

7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register**.

The following transactions were granted early termination of the waiting period provided by law and the premerger notification rules. The grants were made by the Federal Trade Commission and the Assistant Attorney General for the Antitrust Division of the Department of Justice. Neither agency intends to take any action with respect to these proposed acquisitions during the applicable waiting period.

Transaction No.	Acquiring person	Acquired person	Acquired entities
Transactions Granted Early Termination—12/27/2001			
20020202	General Electric Company	CMS Energy Corporation	Michigan Electric Transmission Company LLC
20020204	AT&T Wireless Services, Inc.	Gerald T. Vento	THC of Houston, Inc. THC of Melbourne, Inc. THC of Orlando, Inc. THC of San Diego, Inc. THC of Tampa, Inc.
20020216	Furniture Brands International, Inc.	Furnishings International Inc.	Drexel Heritage Furnishings, Inc. Furnishings International Inc. Henredon Furniture Industries, Inc. Maitland-Smith Pacific, LTD Maitland-Smith, Inc.
20020242	Perot Systems Corporation	Dianne H. Patterson	Claim Services Resources Group, Inc.
20020252	Omnicare, Inc.	Mariner Post-Acute Network, Inc. ..	American Medical Insurance Billing Services, Inc. American Pharmaceutical Services, Inc. APS Pharmacy Management, Inc. Compass Pharmacy Services of Maryland, Inc. Compass Pharmacy Services of Maryland, Inc. Ocean Pharmacy, Inc. Pinnacle Pharmaceutical Services, Inc.
Transactions Granted Early Termination—12/28/2001			
20020225	Nestle S.A.	Bristol-Myers Squibb Company	Bristol-Myers Squibb Company
20020226	L. Bettencourt	Bistol-Myers Squibb Company	Bistol-Myers Squibb Company
Transactions Granted Early Termination—01/01/2002			
20020267	American Institute of Certified Public Accountants.	Rivio, Inc.	Rivio, Inc.
20020278	Cable and Wireless Inc.	Exodus Communications, Inc.	Exodus Communications, Inc.
Transactions Granted Early Termination—01/03/2002			
20020275	AOL Time Warner Inc.	Oxygen Media Corporation	Oxygen Media Corporation
20020276	Paul G. Allen	Oxygen Media Corporation	Oxygen Media Corporation
20020282	Berkshire Hathaway Inc.	Craig A. Ponzio	Albecca Inc.

For Further Information Contact:
Sandra M. Peay or Chandra L. Kennedy,
Contact Representatives, Federal Trade
Commission, Premerger Notification
Office, Bureau of Competition, Room
303, Washington, DC 20580, (202) 326-3100.

By Direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 02-1478 Filed 1-18-02; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Healthcare Infection Control Practices Advisory Committee (HICPAC): Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease

Control and Prevention (CDC) announces the following meeting.

Name: Healthcare Infection Control Practices Advisory Committee.

Times and Dates: 8:30 a.m.—5 p.m., February 25, 2002. 8:30 a.m.—4 p.m., February 26, 2002.

Place: Radisson Buckhead/Emory Area Inn, 2061 North Druid Hills Road, Atlanta, Georgia 30329

Status: Open to the public, limited only by the space available.

Purpose: The Committee is charged with providing advice and guidance to the Secretary, the Assistant Secretary for Health, the Director, CDC, and the Director, National Center for Infectious Diseases (NCID), regarding (1) the practice of hospital infection control; (2) strategies for surveillance, prevention, and control of infections (e.g., nosocomial infections), antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of guidelines and other policy statements regarding prevention of healthcare associated infections and healthcare-related conditions.

Matters to be Discussed: Agenda items will include a review of the Draft Guideline for Preventing Transmission of Infectious Agents in Healthcare Settings (formerly Guideline Isolation Precautions in Hospitals) and the Draft Guideline for Prevention of Healthcare-associated Pneumonia; public comments on the Draft Guideline for Hand Hygiene in Healthcare Settings; and updates on CDC activities of interest to the committee.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Michele L. Pearson, M.D., Executive Secretary, HICPAC, Division of Healthcare Quality Promotion, NCID, CDC, 1600 Clifton Road, NE, M/S A-07, Atlanta, Georgia 30333, telephone 404/498-1182.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: January 11, 2002.

Joseph E. Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 02-1220 Filed 1-18-02; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Workshop on Strengthening the Supply of Routinely Recommended Vaccines in the United States

The National Vaccine Advisory Committee (NVAC), of the Centers for Disease Control and Prevention (CDC), announces the following meeting.

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following meeting.

Name: Workshop on Strengthening the Supply of Routinely Recommended Vaccines in the United States.

Times and Dates: 8:30 a.m.—5 p.m., February 11, 2002. 8:30 a.m.—4 p.m., February 12, 2002.

Place: Omni Shoreham Hotel, 2500 Calvert Street, Washington, DC, Phone: 1-888-511-5743.

Status: Open to the public, limited only by the space available. The meeting rooms will accommodate approximately 200 people.

Purpose: The objectives of the Workshop are to define and describe the scope of the problem with vaccine supply in the United States; to identify and discuss possible contributing causes of and potential strategies to address the vaccine supply problem; and, to develop a limited number of pragmatic strategy options to address the vaccine supply issues in the United States.

Matters to be Discussed: Agenda items will include presentations and discussion including: an overview of the problems associated with vaccine supply; financial incentives for research, development, and production; review of the regulatory process; government-owned contractor-operated vaccine production facilities; vaccine stockpiles; liability protections; tailoring strategies to specific shortages; and, perspectives of constituencies.

Agenda items are subject to change as priorities dictate.

Contact Persons for More Information: Stephen Sepe and Jeanne Santoli, CDC, 1600 Clifton Road, NE, Atlanta, Georgia 30333, telephone 770-488-2040 (Sepe) and 404/639-8802 (Santoli). You may also visit the NVPO web site for additional information: www.cdc.gov/od/nvpo/calendar.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** Notices pertaining to announcements of meetings and other committee

management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: January 11, 2002.

Joseph E. Salter,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 02-1221 Filed 1-18-02; 8:45 am]

BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Advisory Board on Radiation and Worker Health: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting.

Name: Advisory Board on Radiation and Worker Health (ABRWH).

Times and Dates: 9 a.m.—5 p.m., February 13, 2002. 8:30 a.m.—3 p.m., February 14, 2002.

Place: Washington Court Hotel on Capitol Hill, 525 New Jersey Avenue, NW., Washington, DC 20001, telephone 202/628-2100, fax 202/879-7938.

Status: Open to the public, limited only by the space available. The meeting room accommodates approximately 65 people.

Background: The Advisory Board on Radiation and Worker Health (the Board) was established under the *Energy Employees Occupational Illness Compensation Program Act of 2000* to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Board include providing advice on the development of probability of causation guidelines which are being promulgated by Department of Health and Human Services (HHS), advice on methods of dose reconstruction which have been promulgated as an interim final rule, evaluation of the validity and quality of dose reconstructions conducted by the National Institute for Occupational Safety and Health (NIOSH) for qualified cancer claimants, and advice on the addition of classes of workers to the Special Exposure Cohort.

In December 2000, the President delegated responsibility for funding, staffing, and operating the Board to HHS, which subsequently delegated this